The latest price target for Marker Therapeutics (NASDAQ:MRKR) was reported by Ladenburg Thalmann on April 30, 2024. The analyst firm set a price target for $11.00 expecting MRKR to rise to within 12 months (a possible 127.27% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Marker Therapeutics (NASDAQ:MRKR) was provided by Ladenburg Thalmann, and Marker Therapeutics initiated their buy rating.

There is no last upgrade for Marker Therapeutics

The last downgrade for Marker Therapeutics Inc happened on February 17, 2022 when Roth Capital changed their price target from $3 to $1 for Marker Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marker Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marker Therapeutics was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.

While ratings are subjective and will change, the latest Marker Therapeutics (MRKR) rating was a initiated with a price target of $0.00 to $11.00. The current price Marker Therapeutics (MRKR) is trading at is $4.84, which is within the analyst’s predicted range.